Tag - BLRX

Markets

Maxim doubles BioLineRx PT to $10 from $5

Maxim Group raised its price target for BioLineRx (NASDAQ:BLRX) to $10 from $5 on positive top-line data from the company’s Phase 3 GENESIS trial. The stock was quoted at $5.30, up $2.11, in afternoon trading on...

May 4, 2021

Developments

BioLineRx initiates Phase 2 first-line metastatic pancreatic cancer trial

BioLineRx (NASDAQ:BLRX) launched a Phase 2 trial evaluating motixafortide, in combination with cemiplimab and standard-of-care chemotherapy, in first-line metastatic pancreatic ductal adenocarcinoma (PDAC)...

October 29, 2020

Developments

BioLineRx gets EMA orphan drug designation for pancreatic cancer drug

BioLineRx (NASDAQ:BLRX) received European Medicines Agency orphan drug designation (ODD) for motixafortide for the treatment of pancreatic cancer. Motixafortide is a short synthetic peptide designed to target CXCR4, a...

January 14, 2020

Markets

Maxim lowers BioLineRx PT to $2 from $3

Maxim Group reduced its price target for BioLineRx (NASDAQ:BLRX) to $2 from $3 after the company reported fourth quarter results. The stock was quoted at $1 in afternoon trading on March 6. BioLineRx, which focuses on...

March 6, 2018

Tag - BLRX

Maxim doubles BioLineRx PT to $10 from $5

BioLineRx initiates Phase 2 first-line metastatic pancreatic cancer trial

BioLineRx gets EMA orphan drug designation for pancreatic cancer drug

Maxim lowers BioLineRx PT to $2 from $3

General

More